2,2-bis(bromomethyl)-1,3-propanediol, technical grade: Carcinogenic Potency Database

2,2-Bis(bromomethyl)-1,3-propanediol, technical grade (CAS 3296-90-0)
SMILES, InChI and Structure are below.
Rats and Mice: Cancer Test Summary

Rat Target Sites		Mouse Target Sites		TD₅₀ (mg/kg/day)
Male	Female	Male	Female	Rat	Mouse
eso ezy hmo lgi lun mgl orc per ski smi sto sub tes thy ubl	eso mgl orc thy	hag kid lun	hag lun sub	111^m	137^m

Key to the Table Above

Positivity: For each chemical with a positive (carcinogenic) experiment in the Carcinogenic Potency Database (CPDB), results are included on carcinogenic potency (TD₅₀) in each species and target sites in males and females. Positivity is determined by an author’s opinion in a published paper. If all experimental results in the CDPB are negative in a sex-species group, “no positive” appears. If the CPDB has no experiments in the sex-species group, “no test” appears. The summary presents the strongest evidence of carcinogenicity in each group. If there are both positive and negative experiments in a sex-species, the negative results are ignored in this Summary Table.

Target Site Codes: eso = esophagus. ezy = ear/Zymbal’s gland. hag = harderian gland. hmo = hematopoietic system. kid = kidney. lgi = large intestine. lun = lung. mgl = mammary gland. orc = oral cavity (includes tissues of the mouth, oropharynx, pharynx, and larynx). per = peritoneal cavity. ski = skin. smi = small intestine. sto = stomach. sub = subcutaneous tissue. tes = testes. thy = thyroid gland. ubl = urinary bladder. Target sites are listed if any author of published experimental results concluded that tumors were induced in that organ by the test agent. If there is more than one positive experiment in a sex-species, target sites listed may be from more than one experiment, e.g. if liver and lung are both listed, then liver may have been a target in one experiment and lung in another.

TD₅₀: Our standardized measure of carcinogenic potency, TD₅₀, is the daily dose rate in mg/kg body weight/day to induce tumors in half of test animals that would have remained tumor-free at zero dose. Whenever there is more than one positive experiment in a species, the reported TD₅₀ value is a Harmonic Mean calculated using the TD₅₀ value from the most potent target site in each positive experiment.

Superscripts: m = There is more than one positive experiment in the species, and TD₅₀ values from each positive experiment are used in the calculation of the reported Harmonic mean of TD₅₀.

The Carcinogenic Potency Database (CPDB) is a unique and widely used international resource of the results of 6540 chronic, long-term animal cancer tests on 1547 chemicals. The CPDB provides easy access to the bioassay literature, with qualitative and quantitative analyses of both positive and negative experiments that have been published over the past 50 years in the general literature through 2001 and by the National Cancer Institute/National Toxicology Program through 2004. The CPDB standardizes the diverse literature of cancer bioassays that vary widely in protocol, histopathological examination and nomenclature, and in the published author’s choices of what information to provide in their papers. Results are reported in the CPDB for tests in rats, mice, hamsters, dogs, and nonhuman primates.

For each experiment, information is included on species, strain, and sex of test animal; features of experimental protocol such as route of administration, duration of dosing, dose level(s) in mg/kg body weight/day, and duration of experiment; experimental results are provided on target organ, tumor type, and tumor incidence; carcinogenic potency (TD₅₀) and its statistical significance; shape of the dose-response, author’s opinion as to carcinogenicity, and literature citation.

Only tests with dosing for at least ¼ the standard lifespan of the species and experiment length at least ½ the lifespan are included in the CPDB. Only routes of administration with whole body exposure are included. Doses are standardized, average dose rates in mg/kg/day. A description of methods used in the CPDB to standardize the diverse literature of animal cancer tests is presented for: 1) Criteria for inclusion of experiments 2) Standardization of average daily dose levels and 3) TD₅₀ estimation for a standard lifespan. See Methods for other details.

TD₅₀ provides a standardized quantitative measure that can be used for comparisons and analyses of many issues in carcinogenesis. The range of TD₅₀ values across chemicals that are rodent carcinogens is more than 100 million-fold. More than half the chemicals tested are positive in at least one experiment.

A plot of all results on each experiment in the CPDB for this chemical is presented below. These results are the source information for the Cancer Test Summary table above.

2,2-Bis(bromomethyl)-1,3-propanediol, technical grade: All Experiments and Citations in CPDB
The definition of each code in the plot below will appear in a pop-up window when the field name in the header line is clicked, e.g., Strain, Site, Path. Each numbered line starts a new experiment and reports protocol information in black. Average daily dose-rates per kg body weight per day are in green. Remaining lines report experimental results in blue.

Abbreviations of fields in header line: # = the line number in the plot of all CPDB chemicals; Xpo = duration of dosing; Xpt = duration of experiment; Site = tissue; Path = tumor type; DR = dose-response; AuOp = author’s opinion about carcinogenicity; LoConf, UpConf = confidence limits (99%) on TD₅₀; Inc = tumor incidence for each dose group.

See Guide to reading the plot for details on each field, using an example of one experiment.

See Help to improve readability, or to fit the plot onto the screen or a printed page.



Chemical (Synonym) CAS
# Species Sex Strain Route Xpo+Xpt PaperNum        0 Dose  1 Dose 2 Dose  3 Dose          Literature Reference or NCI/NTP:Site Path
Site Path Notes   TD50  DR Pval    AuOp LoConf UpConf   Cntrl   1 Inc  2 Inc   3 Inc                                                        Brkly Code


2,2-BIS(BROMOMETHYL)-1,3-PROPANEDIOL, TECHNICAL GRADE  (DIBROMONEOPENTYL GLYCOL) 3296-90-0
732  M f b6c eat 24m25 TR452 :                       0    39.9mg  79.9mg  160.mg
 MXB MXB        67.8mg * P<.0005    45.6mg 118.mg   8/52   17/50   27/51   32/50        hag:ade,anb,car; lun:a/a,a/c; sub:fbs,sar. C
 hag MXA        122.mg * P<.0005 c  76.2mg 254.mg   3/52   12/50   13/51   19/50                                  hag:ade,anb,car.
 lun MXA        127.mg * P<.0005 c  77.3mg 263.mg   5/52    5/50   15/51   19/50                                      lun:a/a,a/c.
 lun a/a        171.mg Z P<.0005    101.mg 367.mg   3/52    3/50    9/51   17/50                                                   S
 hag MXA        187.mg * P<.0005    109.mg 429.mg   2/52    6/50    8/51   15/50                                      hag:ade,anb. S
 sub MXA        322.mg * P<.0005 c  176.mg 656.mg   0/52    1/50    4/51   12/50                                      sub:fbs,sar.
 hag car        323.mg * P<.003     161.mg 2.27gm   1/52    6/50    5/51    7/50                                                   S
 sub sar        350.mg * P<.0005 c  188.mg 737.mg   0/52    1/50    4/51   11/50
 lun a/c        398.mg * P<.008     176.mg 9.86gm   2/52    2/50    6/51    5/50                                                   S
 for sqp        446.mg * P<.002  e  206.mg 1.90gm   0/52    1/50    5/51    3/50
 liv hpa        301.mg Z P<.05      116.mg n.s.s.  16/52   12/50    5/51   16/50                                                   S
 --- MXA        846.mg * P<.03   e  307.mg n.s.s.   1/52    2/50    0/51    5/50                                      ---:hem,hes.
 mgl car        1.48gm * P<.02   e  472.mg n.s.s.   0/52    0/50    1/51    3/50
 --- hes        1.48gm * P<.02      437.mg n.s.s.   0/52    0/50    0/51    3/50                                                   S
 TBA MXB        57.3mg * P<.0005    33.5mg 153.mg  35/52   42/50   43/51   42/50
 liv MXB        267.mg Z P<.08      99.3mg n.s.s.  20/52   19/50    9/51   18/50                                  liv:hpa,hpb,hpc.
 lun MXB        127.mg * P<.0005    77.3mg 263.mg   5/52    5/50   15/51   19/50                                      lun:a/a,a/c.
733  M m b6c eat 24m24 TR452 :                       0    37.2mg  74.4mg  149.mg
 MXB MXB        106.mg * P<.0005    60.8mg 321.mg  18/50   18/51   28/50   37/49        hag:ade,anb,car,cnb; kid:rua; lun:a/a,a/c. C
 hag MXA        155.mg * P<.0005 c  96.0mg 347.mg   4/50    7/51   16/50   22/49                              hag:ade,anb,car,cnb.
 hag MXA        191.mg * P<.0005    114.mg 481.mg   3/50    6/51   12/50   18/49                                      hag:ade,anb. S
 lun MXA        218.mg * P<.007  c  106.mg 3.37gm  15/50   11/51   16/50   25/49                                      lun:a/a,a/c.
 lun a/a        270.mg Z P<.005     133.mg 2.59gm  12/50    4/51   12/50   21/49                                                   S
 lun a/c        334.mg * P<.008     161.mg 8.52gm   3/50    7/51    8/50   11/49                                                   S
 for MXA        581.mg * P<.02   e  283.mg n.s.s.   0/50    3/51    3/50    4/49                                      for:sqc,sqp.
 thy fca        835.mg * P<.04      360.mg n.s.s.   0/50    3/51    0/50    4/49                                                   S
 kid rua        1.19gm * P<.03   c  451.mg n.s.s.   0/50    0/51    3/50    2/49
 TBA MXB        126.mg * P<.04      54.4mg n.s.s.  37/50   42/51   45/50   45/49
 liv MXB        2.48gm * P<.9       144.mg n.s.s.  27/50   32/51   27/50   23/49                                  liv:hpa,hpb,hpc.
 lun MXB        218.mg * P<.007     106.mg 3.37gm  15/50   11/51   16/50   25/49                                      lun:a/a,a/c.
734  R f f34 eat 24m24 TR452 :                       0    124.mg  248.mg  496.mg
 mgl fba        83.0mg * P<.0005 c  56.7mg 138.mg  25/50   45/51   46/53   45/52
 mgl MXA        83.0mg * P<.0005    56.7mg 138.mg  25/50   45/51   46/53   45/52                                      mgl:ade,fba. S
 mgl MXA        83.8mg * P<.0005 c  57.0mg 141.mg  27/50   47/51   47/53   47/52                                  mgl:ade,car,fba.
 MXB MXB        84.3mg * P<.0005    57.2mg 142.mg  28/50   47/51   48/53   47/52   eso:sqp; mgl:ade,car,fba; pal:sqc,sqp; thy:fca,
                                                                                                                 fcc; ton:sqc,sqp. C
 pit pda        300.mg * P<.002     155.mg 1.43gm  16/50   24/51   24/53   15/52                                                   S
 --- mnl        406.mg * P<.0005    220.mg 1.38gm  15/50   13/51   19/53   19/52                                                   S
 MXA MXA        1.01gm * P<.003  c  452.mg 7.37gm   2/50    3/51    5/53    6/52                         pal:sqc,sqp; ton:sqc,sqp.
 MXA sqp        1.24gm * P<.008     505.mg 29.9gm   2/50    2/51    4/53    5/52                                 pal:sqp; ton:sqp. S
 ton MXA        1.26gm * P<.004     539.mg 9.28gm   1/50    2/51    4/53    5/52                                      ton:sqc,sqp. S
 ton sqp        1.36gm * P<.007     559.mg 27.0gm   1/50    2/51    4/53    4/52                                                   S
 eso sqp        1.41gm Z P<.0005 c  669.mg 3.36gm   0/50    0/51    1/53   10/52
 thy MXA        1.67gm * P<.002  c  641.mg 7.11gm   0/50    0/51    2/53    4/52                                      thy:fca,fcc.
 thy fca        2.16gm * P<.004     763.mg 14.7gm   0/50    0/51    2/53    3/52                                                   S
 ute MXA        859.mg * P<.03      349.mg n.s.s.   5/50    9/51    6/53    6/52                                      ute:esp,ess. S
 ute esp        904.mg * P<.03      366.mg n.s.s.   5/50    8/51    6/53    6/52                                                   S
 sub MXA        1.37gm * P<.02      531.mg n.s.s.   2/50    4/51    1/53    6/52                                  sub:fbs,fib,sar. S
 sub MXA        4.20gm Z P<.04      1.16gm n.s.s.   1/50    0/51    0/53    4/52                                      sub:fbs,sar. S
 TBA MXB        94.4mg * P<.0005    61.0mg 179.mg  45/50   51/51   53/53   52/52
 liv MXB        no dre   P=1.       n.s.s. n.s.s.   0/50    0/51    0/53    0/52                                  liv:hpa,hpb,hpc.
735  R m f34 eat 24m24 TR452 :                       0    99.4mg  199.mg  398.mg
 tes MXA        66.5mg Z P<.0005    41.6mg 132.mg  49/51   48/53   51/51   51/55                                      tes:iab,ica. S
 MXB MXB        68.1mg * P<.0005    44.9mg 117.mg  33/51   37/53   49/51   52/55  ---:mnl,msm; col:adp; eso:sqp; gnv:sqc; jej:car;
                                lun:a/a,a/c; mgl:ade,fba; pal:sqp; ski:bca,bcc,ker,sqc,sqp,tri; sub:fbs,fib,sar; thy:fca,fcc; ton:
                                                                                                    sqp; ubl:tcc,tpp; zym:ade,car. C
 --- mnl        95.8mg * P<.0005 c  58.8mg 194.mg  27/51   29/53   40/51   34/55
 ski MXA        166.mg Z P<.0005 c  103.mg 300.mg   4/51    6/53   14/51   24/55                      ski:bca,bcc,ker,sqc,sqp,tri.
 pni MXA        208.mg Z P<.006     86.1mg 2.46gm   1/51    8/53   (1/51    0/55)                                     pni:isa,isc. S
 sub MXA        221.mg * P<.0005 c  131.mg 437.mg   2/51    9/53   13/51   16/55                                  sub:fbs,fib,sar.
 ski ker        235.mg Z P<.0005    135.mg 488.mg   3/51    5/53   11/51   16/55                                                   S
 mgl MXA        262.mg * P<.0005 c  143.mg 542.mg   0/51    4/53    7/51    7/55                                      mgl:ade,fba.
 sub fib        271.mg * P<.0005    156.mg 568.mg   2/51    8/53   11/51   15/55                                                   S
 mgl fba        275.mg * P<.0005    147.mg 597.mg   0/51    4/53    6/51    6/55                                                   S
 MXA MXA        285.mg * P<.0005 c  157.mg 555.mg   0/51    4/53    9/51   10/55                        gnv:sqc; pal:sqp; ton:sqp.
 MXA sqp        300.mg * P<.0005    163.mg 601.mg   0/51    4/53    8/51   10/55                                 pal:sqp; ton:sqp. S
 --- msm        335.mg * P<.0005 c  177.mg 690.mg   0/51    3/53    8/51    9/55
 ton sqp        500.mg * P<.0005    239.mg 1.19gm   0/51    2/53    5/51    8/55                                                   S
 pan ana        516.mg * P<.003  e  218.mg 3.81gm   1/51    2/53    4/51    3/55
 thy MXA        629.mg * P<.0005 c  280.mg 2.10gm   0/51    2/53    6/51    3/55                                      thy:fca,fcc.
 ski MXA        720.mg Z P<.0005    319.mg 2.10gm   0/51    1/53    2/51    6/55                                  ski:bca,bcc,tri. S
 lun MXA        729.mg * P<.003  c  287.mg 5.65gm   1/51    1/53    3/51    4/55                                      lun:a/a,a/c.
 pal sqp        808.mg * P<.005     314.mg 8.16gm   0/51    2/53    3/51    2/55                                                   S
 col adp        997.mg * P<.0005 c  386.mg 3.80gm   0/51    0/53    3/51    4/55
 sub MXA        1.08gm * P<.003     381.mg 7.58gm   0/51    1/53    2/51    3/55                                      sub:fbs,sar. S
 ski MXA        1.13gm * P<.005     376.mg 12.3gm   1/51    0/53    2/51    5/55                                      ski:sqc,sqp. S
 ski sqp        1.13gm * P<.005     376.mg 12.3gm   1/51    0/53    2/51    5/55                                                   S
 lun a/c        1.30gm Z P<.006     403.mg 18.8gm   0/51    1/53    0/51    3/55                                                   S
 eso sqp        1.39gm * P<.0005 c  472.mg 5.95gm   0/51    0/53    1/51    5/55
 ski bca        1.53gm * P<.007     483.mg 28.5gm   0/51    1/53    0/51    3/55                                                   S
 sub sar        1.55gm * P<.004     499.mg 11.5gm   0/51    0/53    2/51    3/55                                                   S
 kid rua        1.55gm * P<.004  e  532.mg 11.4gm   0/51    0/53    1/51    3/55
 zym ade        1.95gm * P<.007     532.mg 31.5gm   0/51    0/53    1/51    3/55                                                   S
 ubl MXA        2.32gm * P<.009  c  577.mg 79.4gm   0/51    0/53    1/51    3/55                                      ubl:tcc,tpp.
 pit MXA        462.mg * P<.03      177.mg n.s.s.   7/51   10/53    6/51    6/55                                      pit:pda,pdc. S
 pit pda        493.mg * P<.04      187.mg n.s.s.   7/51    9/53    6/51    6/55                                                   S
 thy MXA        675.mg Z P<.05      236.mg n.s.s.   8/51    4/53    5/51    6/55                                  thy:cca,ccb,ccr. S
 pre MXA        793.mg * P<.05      276.mg n.s.s.   5/51    4/53    5/51    5/55                                      pre:ade,car. S
 pre ade        819.mg * P<.04      286.mg n.s.s.   3/51    3/53    4/51    4/55                                                   S
 thy fcc        1.11gm * P<.02      388.mg n.s.s.   0/51    1/53    4/51    1/55                                                   S
 zym MXA        1.60gm * P<.03   c  547.mg n.s.s.   2/51    1/53    4/51    5/55                                      zym:ade,car.
 thy MXA        1.92gm * P<.05      580.mg n.s.s.   1/51    1/53    1/51    3/55                                      thy:ccb,ccr. S
 jej car        5.66gm * P<.04   c  1.35gm n.s.s.   0/51    0/53    0/51    2/55
 for sqp        16.0gm * P<.2       2.60gm n.s.s.   0/51    0/53    0/51    1/55
 sev MXA        no dre   P=1.       n.s.s. n.s.s.   0/51    0/53    0/51    0/55                                      sev:ade,car.
 TBA MXB        63.8mg * P<.0005    40.7mg 120.mg  44/51   50/53   51/51   53/55
 liv MXB        1.84gm * P<.5       453.mg n.s.s.   0/51    2/53    0/51    0/55                                  liv:hpa,hpb,hpc.
736  R m f34 eat  3m24 TR452a : ()                   0    99.5mg
 tes MXA        5.94mg   P<.0005    3.14mg 12.2mg  49/51   59/60                                                      tes:iab,ica. S
 ski MXA        16.9mg   P<.0005    5.27mg 53.2mg   4/51   21/60                                          ski:bca,ker,sqc,sqp,tri. S
 ski MXA        21.7mg   P<.0005    5.14mg 99.9mg   1/51   12/60                                                      ski:sqc,sqp. S
 --- mnl        22.5mg   P<.0005    9.89mg 69.4mg  27/51   25/60                                                                   S
 pre ade        22.8mg   P<.0005    5.68mg 215.mg   3/51    4/60                                                                   S
 MXA MXA        24.0mg   P<.0005    5.25mg 113.mg   0/51   13/60                                             pal:sqc,sqp; ton:sqp. S
 MXA sqp        24.6mg   P<.0005    5.27mg 127.mg   0/51   12/60                                                 pal:sqp; ton:sqp. S
 --- msm        28.4mg   P<.0005    12.4mg 58.8mg   0/51   26/60                                                                   S
 ton sqp        30.8mg   P<.0005    5.38mg 446.mg   0/51    6/60                                                                   S
 pre MXA        39.0mg   P<.004     8.59mg 724.mg   5/51    4/60                                                      pre:ade,car. S
 ski ker        42.5mg   P<.0005    12.5mg 184.mg   3/51   10/60                                                                   S
 ski sqp        46.2mg   P<.0005    12.5mg 164.mg   1/51   11/60                                                                   S
 lun MXA        52.4mg   P<.0005    8.26mg 348.mg   1/51    7/60                                                      lun:a/a,a/c. S
 ski MXA        64.6mg   P<.0005    21.9mg 229.mg   0/51    7/60                                                      ski:bca,tri. S
 lun a/a        73.1mg   P<.004     8.47mg 1.42gm   1/51    4/60                                                                   S
 mgl fba        78.3mg   P<.0005    26.8mg 330.mg   0/51    5/60                                                                   S
 ski bca        82.3mg   P<.0005    24.3mg 348.mg   0/51    6/60                                                                   S
 thy MXA        82.6mg   P<.0005    28.4mg 273.mg   0/51    9/60                                                      thy:fca,fcc. S
 sub MXA        87.3mg   P<.0005    18.4mg 430.mg   2/51   10/60                                                  sub:fbs,fib,sar. S
 sub fib        111.mg   P<.003     20.2mg 1.06gm   2/51    7/60                                                                   S
 pal sqp        115.mg   P<.0005    34.3mg 434.mg   0/51    7/60                                                                   S
 thy fca        132.mg   P<.0005    41.9mg 495.mg   0/51    7/60                                                                   S
 zym MXA        138.mg   P<.0005    64.3mg 412.mg   2/51   15/60                                                  zym:ade,car,cnb. S
 zym MXA        138.mg   P<.0005    64.3mg 412.mg   2/51   15/60                                                      zym:car,cnb. S
 MXA MXA        146.mg   P<.0005    61.1mg 377.mg   0/51   11/60                                             col:adp,car; rec:adp. S
 MXA adp        152.mg   P<.0005    62.1mg 415.mg   0/51   10/60                                                 col:adp; rec:adp. S
 for sqp        217.mg   P<.0005 c  72.9mg 1.00gm   0/51    5/60
 ubl MXA        223.mg   P<.007     53.3mg 6.51gm   0/51    2/60                                                      ubl:tcc,tpp. S
 lun a/c        327.mg   P<.007     85.0mg 5.55gm   0/51    3/60                                                                   S
 MXA MXA        363.mg   P<.003     130.mg 2.05gm   0/51    5/60                                             ilm:car; jej:adp,car. S
 MXA car        445.mg   P<.006     143.mg 5.40gm   0/51    4/60                                                 ilm:car; jej:car. S
 pit pda        67.3mg   P<.03      14.5mg n.s.s.   7/51    5/60                                                                   S
 pan ana        193.mg   P<.05      16.8mg n.s.s.   1/51    3/60                                                                   S
 sev MXA h      453.mg   P<.03   c  91.5mg n.s.s.   0/51    2/60                                                      sev:ade,car.
 lun sqc        484.mg   P<.02      111.mg n.s.s.   0/51    3/60                                                                   S
 sub MXA        654.mg   P<.02      188.mg n.s.s.   0/51    3/60                                                      sub:fbs,sar. S
 kid rua        970.mg   P<.1       158.mg n.s.s.   0/51    1/60
 eso sqp        no dre   P=1.       n.s.s. n.s.s.   0/51    0/60
 TBA MXB        6.25mg   P<.0005    3.31mg 12.9mg  51/51   60/60
 liv MXB        702.mg   P<.08      114.mg n.s.s.   0/51    1/60                                                  liv:hpa,hpb,hpc.
737  R f sss eat 24m24 1642                          0    5.00mg  100.mg                                     Keyes;jctx,7,77-98;1980
 liv hph e      2.55gm * P<.5    -  409.mg n.s.s.   3/48    0/50    3/50
 liv hpc e      no dre   P=1.    -  49.1mg n.s.s.   1/48    0/50    0/50
 tba mix e      1.73gm * P<1.    -  23.6mg n.s.s.  47/50   49/50   48/50
738  R m sss eat 24m24 1642                          0    5.00mg  100.mg
 liv hph e      no dre   P=1.    -  49.1mg n.s.s.   1/50    0/50    0/50
 liv hpc e      no dre   P=1.    -  1.01gm n.s.s.   1/50    1/50    0/50
 tba mix e      no dre   P=1.    -  74.9mg n.s.s.  39/50   40/50   39/50

Mutagenicity in Salmonella: positive
SMILES Code for 2,2-Bis(bromomethyl)-1,3-propanediol, technical grade: OCC(CO)(CBr)CBr
InChI Code for 2,2-Bis(bromomethyl)-1,3-propanediol, technical grade: InChI=1/C5H10Br2O2/c6-1-5(2-7,3-8)4-9/h8-9H,1-4H2
Source for SMILES and InChI: USEPA Distributed Structure-Searchable Toxicity (DSSTox) Database

Chemical Structure for 2,2-Bis(bromomethyl)-1,3-propanediol, technical grade:

Source for structure: National Library of Medicine ChemIDPlus

See full CPDB Summary Table on 1547 chemicals. See Full CPDB for all results on 6540 experiments of 1547 chemicals.

A complete list of CPDB chemicals, which is searchable by name or by CAS number, is available here.

For a compendium of CPDB results organized by target organ, which lists all chemicals in each species that induced tumors in each of 35 organs, see Summary Table by Target Organ.

The CPDB is available in several formats that permit printing and downloading into spreadsheets and statistical databases.

A plot of the CPDB presents results of 1547 experiments on 6540 chemicals in an easily readable format that has been used in publications of the CPDB.
A Screen version plot for use on a single computer screen, with the same data.
Excel version of the same data.
Tab-separated versions of the same data, which can be easily read into databases.

A Supplementary Dataset gives details on dosing and survival for each experiment.

Relatively precise estimates of the lower confidence limit on the TD₁₀ (LTD₁₀) are readily calculated from the TD₅₀ and its lower confidence limit, which are reported in the CPDB. For researchers and regulatory agencies interested in LTD₁₀ values, we provide them in an Excel spreadsheet.

PDF versions of our publications of analyses using the CPDB are available, organized by year and by research topic.

Carcinogenic Potency Database Project (CPDB) Home Page
For more information about this Web Page, contact Specialized Information Services (support@leadscope.com).
Last updated: October 3, 2007

PDF documents are best viewed with the free Adobe® Reader http://get.adobe.com/reader
Excel documents are best viewed with the free Excel® Viewer http://www.microsoft.com/en-us/download/details.aspx?id=10